Medtronic plc Stock
€87.68
Your prediction
Medtronic plc Stock
Pros and Cons of Medtronic plc in the next few years
Pros
Cons
Performance of Medtronic plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Medtronic plc | 0.070% | -2.101% | 11.235% | 7.973% | 13.718% | 15.899% | -6.648% |
| Henry Schein Inc. | 1.010% | -3.758% | 0.160% | -11.826% | -6.355% | -21.011% | 10.780% |
| Dexcom Inc. | 1.680% | 3.911% | 5.198% | -27.261% | -25.748% | -50.018% | -21.895% |
| Zimmer Holdings | 1.170% | -4.568% | -11.254% | -24.288% | -21.495% | -30.873% | -35.122% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first glance at Medtronic's financials, the company appears to be a strong player in the Healthcare Equipment & Supplies sector. Over the years, Medtronic has demonstrated relatively stable financial performance, which is a desirable attribute for a healthcare company. However, more in-depth analysis is needed to better understand the pros and cons of its financial situation.
Revenue Growth: Medtronic's total revenue has experienced consistent growth over the last three years as seen in the yearly income statements. In 2020, the company recorded total revenue of $28.913 billion which increased to $30.117 billion in 2021, and further to $31.686 billion in 2022.
Increasing Gross Profit: Medtronic has seen a rise in its gross profit, from $19.489 billion in 2020 to $19.634 billion in 2021, and eventually $21.541 billion in 2022. This implies that the company is becoming more efficient in its manufacturing and supply chain activities, which is a good sign for potential investors.
Comments
News
Prediction: 1 Healthcare Giant Set to Soar in 2026
Medtronic (NYSE: MDT), a medical device specialist, has lagged the market over the past five years. The company has experienced slow revenue growth, significant competition in some of its niches --
This Medtech Giant's Stock Is Soaring. Should You Buy It Ahead of 2026?
It's been a good year for Medtronic (NYSE: MDT), a medical device specialist. Despite the threat of tariffs, the healthcare leader has generally delivered strong financial results and has
Which 'Dividend Prince' Will Become The Next King In 2 Years?
Dividend Kings are the royalty of dividend stocks. These companies have increased their payments every single year for half a century. It's an elite group, with only 56 companies currently meeting